{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=24", "query": { "intervention": "antibody-drug conjugate", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 503, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T16:39:31.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03364348", "title": "4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Utomilumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Ado-Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George W. Sledge Jr.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-10-30", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2022-10-19", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03364348" }, { "nct_id": "NCT07667335", "title": "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma" ], "interventions": [ { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2026-10-20", "completion_date": "2029-07-16", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07667335" }, { "nct_id": "NCT03543813", "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Head and Neck Cancer", "Non Small Cell Lung Cancer", "Diffuse Large B Cell Lymphoma", "Esophageal Cancer" ], "interventions": [ { "name": "CX-2029", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2018-06-15", "completion_date": "2023-06-01", "has_results": false, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543813" }, { "nct_id": "NCT06234423", "title": "A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Solid Tumor" ], "interventions": [ { "name": "CUSP06", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OnCusp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 263, "start_date": "2024-02-09", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 14, "location_summary": "Denver, Colorado • New Haven, Connecticut • Miami Beach, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06234423" }, { "nct_id": "NCT03113500", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult T-Cell Leukemia/Lymphoma", "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Angioimmunoblastic T-Cell Lymphoma", "Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Hepatosplenic T-Cell Lymphoma", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-12-04", "completion_date": "2027-04-25", "has_results": true, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 4, "location_summary": "Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113500" }, { "nct_id": "NCT06758401", "title": "This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Non-Small-Cell Lung (NSCLC)" ], "interventions": [ { "name": "Sigvotatug Vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 714, "start_date": "2025-07-23", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 84, "location_summary": "Fullerton, California • Golden, Colorado • Grand Junction, Colorado + 56 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06758401" }, { "nct_id": "NCT07225959", "title": "A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "MK-1406 Injection", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 400, "start_date": "2025-10-29", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 4, "location_summary": "Miami Lakes, Florida • Spartanburg, South Carolina", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225959" }, { "nct_id": "NCT06034470", "title": "Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pivekimab Sunirine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-12-18", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06034470" }, { "nct_id": "NCT02822586", "title": "TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mycosis Fungoides", "Sézary Syndrome" ], "interventions": [ { "name": "TSEB Therapy", "type": "RADIATION" }, { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2016-12-19", "completion_date": "2019-04-29", "has_results": false, "last_update_posted_date": "2019-08-30", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02822586" }, { "nct_id": "NCT01712490", "title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1334, "start_date": "2012-11-09", "completion_date": "2026-02-02", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-09T16:39:31.022Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712490" } ] }